The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.
Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific ...
*** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral ...
(RTTNews) - Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive ...
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy ExpertsAntoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results